Home / Ophthalmology consulting
Ophthalmology and retina consulting for investors and industry
Clinically grounded advice on retina therapies, devices, AI and companies, from a practicing retina surgeon, clinical trial investigator and physician entrepreneur.
Why a practicing retina specialist
Billions of dollars ride on how retina drugs and devices perform once they reach the clinic. Trial results, label claims and market models only tell part of the story. The rest depends on how retina specialists actually choose treatments, how a therapy fits into a busy injection clinic, what payers will cover, and what patients will tolerate.
Dr. Joshua Mali brings that real-world view. He is a board-certified, fellowship-trained retina specialist and vitreoretinal surgeon, a principal investigator on five retina clinical trials, the author of the annual Top 5 in Ophthalmology forecasts, and the co-developer of a patented ophthalmic device. Through Mali Enterprises, he turns that experience into practical guidance for the companies and investors shaping eye care.
Who he works with
Pharmaceutical and biotech
Pipeline, positioning, launch and lifecycle strategy for retina therapeutics.
Medical device, diagnostics and AI
Product design, workflow fit and commercialization for surgical, imaging, monitoring and AI tools.
Investors
Venture capital, private equity, hedge funds and investment banks evaluating ophthalmic assets.
Research and expert networks
Market research, physician panels and expert consultations on retina practice.
Advisory services
Investment due diligence
Clinical and commercial assessment of ophthalmic companies, drugs and devices: trial data, differentiation, safety signals, likely uptake and the risks a practicing physician sees.
Market and competitive landscape
Where the retina market is heading, from anti-VEGF agents, bispecifics and biosimilars to geographic atrophy, sustained delivery and gene therapy.
AI and digital health strategy
Clinical validity, workflow fit, physician trust and the path to adoption for AI imaging, diagnostic and monitoring tools. More on AI in ophthalmology.
Advisory boards and KOL engagement
Candid input on pipelines, product positioning, messaging and unmet needs in retinal disease.
Clinical development strategy
Trial design, endpoints, site operations and patient recruitment, informed by principal investigator experience with Allergan, Regeneron, Santen, Opthea and Chengdu Kanghong.
Commercialization and launch
How retina specialists adopt new treatments, including practice workflow, reimbursement, managed care, payer and pharmacy considerations.
Device and product innovation
Concept-to-market guidance from a physician who patented the Mali Eyeglass Holder and helped develop the SNAPS Eyeshield.
Expert consultations, panels and keynotes
One-on-one calls, investor events, conference panels and corporate talks on the state of ophthalmology.
Areas of focus
- Neovascular AMD
- Geographic atrophy and complement inhibition
- Diabetic retinopathy and DME
- Retinal vein occlusion
- Uveitis
- Anti-VEGF and bispecific therapies
- High-dose and longer-acting agents
- Biosimilars
- Sustained-release and port delivery
- Gene and cell therapy
- AI and home monitoring
- Vitreoretinal surgery and postoperative care
The experience behind the advice
- Principal investigator on five retina clinical trials, including SEQUOIA (Allergan), PANORAMA (Regeneron) and OPT-302-1004 (Opthea).
- Author of the annual Top 5 in Ophthalmology in Ophthalmology Times since 2016, with forecasts covered by Becker’s ASC Review.
- Author of “Ophthalmology grabs Wall Street’s attention” in Ophthalmology Times.
- Faculty for Pharmacy Times continuing education on managed care in nAMD and DME, and for ScientiaCME programs on geographic atrophy and biosimilars.
- Editorial advisory board member for Ocular Surgery News, Modern Retina, HCPLive and Ophthalmology 360.
- Former Medical Director of the Macular Degeneration Association and Program Chair of Retina Summit 2022.
- Fellow of the American Society of Retina Specialists and oral examiner for the American Board of Ophthalmology.
Common questions
Who does Dr. Mali consult for?
Through Mali Enterprises, Dr. Mali advises pharmaceutical and biotech companies; medical device, diagnostics and AI companies; investors including venture capital, private equity, hedge funds and investment banks; and market research and expert network firms.
What does an ophthalmology due diligence review cover?
A clinical and commercial assessment of an ophthalmic company, drug or device: the trial data, differentiation from current treatments, safety signals, how retina specialists are likely to adopt it, and the practical risks a practicing physician sees.
How do I start an engagement?
Email malienterprisesglobal@gmail.com with a short description of the project, the format you have in mind and your timeline.
Explore more
Discuss an engagement
Due diligence, advisory boards, expert calls, AI strategy or speaking: email Dr. Mali directly.
Email malienterprisesglobal@gmail.com